Rituximab maintenance after bendamustine-based treatment for follicular lymphoma and mantle cell lymphoma may exert a negative influence on SARS-CoV-2 infection outcomes

MLA

Ángel Serna, et al. “Rituximab Maintenance after Bendamustine-Based Treatment for Follicular Lymphoma and Mantle Cell Lymphoma May Exert a Negative Influence on SARS-CoV-2 Infection Outcomes.” Haematologica, vol. 999, no. 1, July 2024. EBSCOhost, https://doi.org/10.3324/haematol.2024.285219.

APA

Ángel Serna, Víctor Navarro, Gloria Iacoboni, Laia López, Juan-Manuel Sancho, Eva González-Barca, Alberto López-García, Raúl Córdoba, Adolfo Sáez, Ana Jiménez Ubieto, Ainara Ferrero, Tomás García, Ángela Sánchez, Cristina García, Marc Bosch, Alba Cabirta, Moraima Jiménez, Ana Marín-Niebla, Francesc Bosch, & Pau Abrisqueta. (2024). Rituximab maintenance after bendamustine-based treatment for follicular lymphoma and mantle cell lymphoma may exert a negative influence on SARS-CoV-2 infection outcomes. Haematologica, 999(1). https://doi.org/10.3324/haematol.2024.285219

Chicago

Ángel Serna, Víctor Navarro, Gloria Iacoboni, Laia López, Juan-Manuel Sancho, Eva González-Barca, Alberto López-García, et al. 2024. “Rituximab Maintenance after Bendamustine-Based Treatment for Follicular Lymphoma and Mantle Cell Lymphoma May Exert a Negative Influence on SARS-CoV-2 Infection Outcomes.” Haematologica 999 (1). doi:10.3324/haematol.2024.285219.